Cargando…
Rheumatherapie und Lungentoxizität
Rheumatic diseases are treated with manifold different drugs that can potentially be pneumotoxic. Adverse effects of drug therapy may induce a wide variety of bronchopulmonary and pleural disorders, which can have a life-threatening course. These side effects rarely have pathognomonic features; ther...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101753/ https://www.ncbi.nlm.nih.gov/pubmed/32288712 http://dx.doi.org/10.1007/s10405-018-0209-3 |
_version_ | 1783511689410379776 |
---|---|
author | Schreiber, J. Müller-Ladner, U. |
author_facet | Schreiber, J. Müller-Ladner, U. |
author_sort | Schreiber, J. |
collection | PubMed |
description | Rheumatic diseases are treated with manifold different drugs that can potentially be pneumotoxic. Adverse effects of drug therapy may induce a wide variety of bronchopulmonary and pleural disorders, which can have a life-threatening course. These side effects rarely have pathognomonic features; therefore, drug-induced diseases are relevant differential diagnoses of pulmonary manifestations of rheumatic diseases, infections, and other independent genuine pulmonary diseases. Diagnosis is based mainly on verification of a compatible disease pattern and exclusion of differential diagnoses, as well as on assessment of the temporal relationship and the consequences of drug abstention. |
format | Online Article Text |
id | pubmed-7101753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-71017532020-03-31 Rheumatherapie und Lungentoxizität Schreiber, J. Müller-Ladner, U. Pneumologe (Berl) Leitthema Rheumatic diseases are treated with manifold different drugs that can potentially be pneumotoxic. Adverse effects of drug therapy may induce a wide variety of bronchopulmonary and pleural disorders, which can have a life-threatening course. These side effects rarely have pathognomonic features; therefore, drug-induced diseases are relevant differential diagnoses of pulmonary manifestations of rheumatic diseases, infections, and other independent genuine pulmonary diseases. Diagnosis is based mainly on verification of a compatible disease pattern and exclusion of differential diagnoses, as well as on assessment of the temporal relationship and the consequences of drug abstention. Springer Medizin 2018-09-25 2018 /pmc/articles/PMC7101753/ /pubmed/32288712 http://dx.doi.org/10.1007/s10405-018-0209-3 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leitthema Schreiber, J. Müller-Ladner, U. Rheumatherapie und Lungentoxizität |
title | Rheumatherapie und Lungentoxizität |
title_full | Rheumatherapie und Lungentoxizität |
title_fullStr | Rheumatherapie und Lungentoxizität |
title_full_unstemmed | Rheumatherapie und Lungentoxizität |
title_short | Rheumatherapie und Lungentoxizität |
title_sort | rheumatherapie und lungentoxizität |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101753/ https://www.ncbi.nlm.nih.gov/pubmed/32288712 http://dx.doi.org/10.1007/s10405-018-0209-3 |
work_keys_str_mv | AT schreiberj rheumatherapieundlungentoxizitat AT mullerladneru rheumatherapieundlungentoxizitat |